New drug combo targets Hard-to-Treat cancers with gene mutation

NCT ID NCT06496568

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 33 times

Summary

This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see if the tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

BC Cancer Vancouver Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Princess Margaret Cancer Center

Toronto, Ontario, M5G 2M9, Canada
Samsung Medical Center

Seoul, 06351, South Korea
Vanderbilt-Ingram Cancer Ctr

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

PIK3CA-MUTATED CANCERS

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

HEAD AND NECK SQUAMOUS CELL CARCINOMA